Pharmacologic class (EPC) · 2 drug pages

SLAMF7-directed immunostimulatory antibody: adverse event reports filed with FDA

3,636 reports list a drug in this class as a suspect or interacting product, 2010–2026.

Read first · FDA's statement on these data

Adverse event reports submitted to FDA do not undergo extensive validation or verification. Therefore, a causal relationship cannot be established between product and reactions listed in a report. While a suspected relationship may exist, it is not medically validated and should not be the sole source of information for clinical decision making or other assumptions about the safety or efficacy of a product. Additionally, it is important to remember that adverse event reports represent a small percentage of total usage numbers of a product. Common products may have a higher number of adverse events due to the higher total number of people using the product. openFDA, FDA

FDA adds: "There is no certainty that the reported event (adverse event or medication error) was actually due to the product. FDA does not require that a causal relationship between a product and event be proven, and reports do not always contain enough detail to properly evaluate an event." The information in these reports "cannot be used to estimate the incidence of these events."

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated.

Not medical advice. This site counts what was reported to FDA. Questions about a medicine or device belong with a pharmacist or clinician.

3,636
reports across the class: 0% of all reports; 123
reports, 12 months to June 2026: 148 in the 12 months before; 87.6%
marked serious by the reporter: 57.4% across all reports; 2
drugs with a page: brand and generic names counted separately

SLAMF7-directed immunostimulatory antibody is a pharmacologic class (an FDA Established Pharmacologic Class) with 2 drug pages on this site. Together those drugs are listed as a suspect or interacting product in 3,636 adverse event reports received by FDA, 0% of the database, from October 2010 to June 2026.

123 reports arrived in the 12 months to June 2026, down 17% from 148 in the 12 months before. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases. 87.6% of the class's reports are marked serious, 20% record death among the outcomes and 44% record hospitalisation, as reported.

Across the class the reactions recorded most often are plasma cell myeloma (10.1%), death (6.6%) and malignant neoplasm progression (6.4%). The class median share shown beside each term is the middle value across the member drugs; it is the comparison used on every drug page in this class.

The members table is ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Drugs in the class

Drug	Name type	Reports	Latest 12 months	Marked serious	Top term recorded
Elotuzumab	generic	2,372	96	97.6%	Plasma cell myeloma
EmplicitiElotuzumab	brand	1,264	27	68.8%	Death

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Reports by month, five years

FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

Reactions recorded across the class

share of class reports recording the termmedian drug in the class

Plasma cell myeloma10.1%369
Deaththe patient died; cause not stated by this term6.6%239
Malignant neoplasm progression6.4%232
Pneumonialung infection5.9%214
Pyrexiafever5.2%189
Drug ineffectivethe medicine did not work as expected4.3%155
Neutropenialow neutrophils, a type of white blood cell4.2%151
Anaemialow red blood cells3.8%137
Thrombocytopenialow platelets3.4%122
Off label useused for a purpose or in a way not on the label2.9%105
Diarrhoealoose or frequent stools2.8%102
Sepsisa severe body-wide response to infection2.7%99
Fatiguetiredness2.6%94
Febrile neutropeniafever with low white blood cells2.2%79
Platelet count decreasedlow platelet count2.1%77
Acute kidney injurysudden loss of kidney function1.9%68
Rashskin rash1.8%67
Infectionan infection, type not specified1.8%65
Nauseafeeling sick1.6%59
Atrial fibrillationan irregular heart rhythm1.6%57
Disease progressionthe disease advanced1.6%57
Covid-19COVID-19 infection1.5%55
Dyspnoeashortness of breath1.5%54
Infusion related reactiona reaction during or soon after an infusion1.5%54
Adverse eventan unwanted medical event, type not specified1.4%52

Solid bar: share of all class reports. Hollow bar: the median share across the 2 member drugs, the reference used on each member's page. One report can record several terms.

Outcomes, patients and reporters

Outcomes recorded

Death20%727

Life-threatening6.2%227

Hospitalisation (initial or prolonged)44%1,600

Disability1%36

Congenital anomaly0%1

Other serious64.4%2,341

Not serious12.4%452

Patient age

Under 20%0

2 to 110%0

12 to 170%0

18 to 441.2%45

45 to 6424.8%901

65 to 7427.4%996

75 and over19.2%697

Age not given27.4%997

Who reported

Physician42.7%1,552

Pharmacist7.6%277

Other health professional40.3%1,464

Lawyer0%1

Consumer or non-health professional9%328

Not given0.4%14

Grey bar: all 20,646,523 reports in the database. Outcome flags are as the reporter set them and are not verified by FDA.

Questions about SLAMF7-directed immunostimulatory antibody reports

Which drugs are in the SLAMF7-directed immunostimulatory antibody class on this site?

Elotuzumab and Empliciti. Class membership comes from the pharmacologic class (EPC) on the drug's FDA label.

How many reports does the class have?

3,636 reports through June 2026, 123 of them in the latest 12 months. A report listing two drugs of the class counts once for each.

What reactions are recorded most often?

plasma cell myeloma (10.1%), death (6.6%), malignant neoplasm progression (6.4%), pneumonia (5.9%) and pyrexia (5.2%).

Can the members table be used to rank the drugs?

No. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." Drugs differ in how many people take them, in the conditions they treat, in time on the market and in how diligently reports are collected.

How do I report an adverse event?

Through FDA MedWatch (Form FDA 3500, or 1-800-FDA-1088) or to the manufacturer. See the guide on how to report.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A class is the Established Pharmacologic Class most often attached to a drug's reports by openFDA's label harmonisation, or from the NDC Directory where reports carry none. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.

Drug data (FAERS) through 30 Jun 2026; device data (MAUDE) through 31 Aug 2026. Not medical advice.